Scripps Wins $8M for Heart Disease Study with Sangamo | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) –The Scripps Translational Science Institute (STSI) and partner Sangamo BioSciences will use a $7.9 million grant from the National Institutes of Health to fund a multidisciplinary study of a region of the human genome thought to be involved in heart disease.

STSI and Sangamo will partner to use induced pluripotent stem (IPS) cells and zinc finger nuclease (ZFN)-based genetic editing in a "disease-in-a-dish" study of the 9p21 region of the genome.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.